If a patient is currently receiving denosumab, this must be discontinued prior to enrollment. Substitution with biphosphonates are acceptable. Subjects with known metastases that are currently involving the lumen of the gastrointestinal tract. Currently receiving experimental treatment with non-approved drugs at the time of enrolment. Patients must undergo a -day washout between last dose and screening CPET. Patients currently receiving active treatment for melanoma Currently receiving exogenous estrogen replacement therapy (topical vaginal estrogen therapy is allowed) Patients who are currently receiving belimumab (a monoclonal antibody for systemic lupus erythematosus) are not eligible Are currently receiving other medications intended for the treatment of their malignancy. Currently using or planning to use: Currently receiving progestin therapy (local, topical, or systemic) Subject currently receiving abiraterone and prednisone for CRPC. Patients currently receiving cancer therapy. Concomitant medications:\r\n* Growth factors that support platelet or white cell number of function must not have been administered within the past days\r\n* Patients with CNS tumors who have not been on a stable or decreasing dose of dexamethasone for the past days\r\n* Patients who are currently receiving another investigational drug\r\n* Patients who are currently receiving other anti-cancer agents\r\n* Allergy or intolerance to agents on this protocol: vincristine, irinotecan, temozolomide, or metformin\r\n* Allergy to cephalosporins\r\n* Patients who have uncontrolled infection, positive blood cultures within the past hours, or receiving treatment for Clostridium difficile infection Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective. Patient currently has unresolved toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study. Is currently receiving and able to discontinue erlotinib, gefinitib, or afatinib. Patients who are currently receiving an anti-IGF-IR monoclonal antibody as part of their treatment regimen Currently receiving radiation or chemotherapy Are currently receiving other medications or radiation intended for the treatment of their malignancy Patient is currently receiving clinical benefit from the treatment with IMCgp, as determined by the principal investigator from the parent study Patients currently receiving chemotherapy/biologic/immunotherapy as these need to be held during FFSRT Currently using hormone replacement therapy (oral or patch) or/and phytoestrogen supplements (i.e. black cohosh) Currently receiving active therapy for other neoplastic disorders Patients currently receiving active therapy for other neoplastic disorders Patients currently receiving any other standard or investigational therapy for the treatment of AML Patients who are currently receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for CTL infusion Patients who are currently receiving angiotensin-converting enzyme (ACE) inhibitors are not eligible due to the development of angioneurotic edema-type reactions in some subjects who received concurrent treatment with temsirolimus + ACE inhibitors Angiotensin-converting enzyme (ACE) inhibitors: patients who are currently receiving ACE inhibitors are not eligible Prior history of receiving afatinib Subjects with a diagnosis of metastatic disease who are currently receiving treatment or who have not been deemed in remission HER therapy naive or currently receiving non-lapatinib HER targeted therapy Currently taking cytotoxic chemotherapy; however, patients receiving non-investigational hormone therapy, lapatinib, and/or trastuzumab are eligible provided these medicines are at a stable dose and were begun more than days prior to the first IT injection Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives Patient is currently benefiting from the treatment with pasireotide, as determined by the investigator Patient must have a medical oncology consult and be recommended to receive or are currently receiving neoadjuvant chemotherapy for a stage IIB through IV carcinoma Patient is currently receiving treatment with ceritinib within a Novartis-sponsored study which has fulfilled the requirements for the primary objective and, in the opinion of the Investigator, would benefit from continued treatment. Patient currently has unresolved toxicities for which ceritinib dosing has been interrupted in the parent study. Patient is currently enrolled in a Novartis-sponsored, CD&MA study receiving everolimus or everolimus plus Sandostatin LAR Depot and has fulfilled all their requirements in the parent study Patient is currently benefiting from treatment with everolimus, as determined by the guidelines of the parent protocol. Patient currently requires systemic therapy. Patient is currently receiving medication(s) that are principally metabolized via the cytochrome P A enzyme pathway. Participants must be currently participating in a PCI- clinical study considered completed and have received at least months of treatment with PCI-. Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated. Currently tolerating treatment in the parent protocol. Currently receiving or has received treatment with systemic steroids in the following dosages within days prior to administration of the first study vaccination. Currently receiving active therapy for other neoplastic disorders Part : currently receiving anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and/or tricyclic drugs (imipramine, clomipramine, or desipramine) Patients currently receiving any medication known to induce central serous chorioretinopathy which in the opinion of the principal investigator, would make the administration of study drug hazardous Receiving phenytoin Women who are currently or planning to breastfeed during protocol treatment Patients who are currently receiving chemotherapy, radiation therapy or are enrolled in another therapeutic clinical trial Not currently receiving therapy A -day washout period is required if patients are currently using another oral topical treatment for mouth lesions; patients currently using clobetasol oral topical treatment are not eligible for this study Currently receiving nivolumab and considered by Investigator to have the potential to derive clinical benefit from continuing treatment with nivolumab. Currently receiving therapy with a UDP-glucuronosyltransferase A inhibitor including diclofenac, imipramine, ketoconazole, mefenamic acid, and probenecid Currently receiving hormone replacement therapy, unless discontinued prior to screening Patient is currently enrolled in an eligible Novartis-sponsored study and receiving ribociclib (LEE) as single agent or in combination with other investigational treatment. Subject must currently be participating in an Astellas sponsored, single agent ASP trial, receiving ASP and have not met any discontinuation criteria of the parent study and can enroll into this rollover study without interruption of study drug, or with no more than weeks interruption in study drug. Patient is currently receiving any of the following medications and cannot be discontinued days prior to starting study drug Ribociclib: Patient is currently receiving any of the following substances and cannot be discontinued days prior to start the treatment: Are currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study Currently receiving cancer therapy. Hydroxyurea will be allowed. Patients who are currently receiving angiotensin-converting enzymes (ACE) inhibitors are not eligible May not be currently prescribed ritonavir, cobacistat and/or zidovudine Patients who have an uncontrolled infection, or who are currently receiving treatment for Clostridium (C) difficile infection Patient currently receiving lithium, steroid, chemotherapy or radiotherapy treatment Are currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study Currently receiving statin therapy or have received any statin therapy within the last months Currently receiving treatment in a different clinical study in which investigational procedures are performed or investigational therapies are administered Subject is currently being treated with anti-epileptics. Patient is currently receiving any of the following medications and cannot be discontinued days prior start if the treatment: Patients who currently have bile duct obstruction or cholelithiasis Active second malignancy, i.e., patient known to have potentially fatal cancer present for which she may be (but not necessarily) currently receiving treatment a. Patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy was completed > months prior and/or bone marrow transplant (BMT) > years prior to first dose of rucaparib Patients who are currently receiving treatment with medications that meet one of the following criteria and that cannot be discontinued at least one week prior to the start of treatment with LGH: Is currently participating in GSK study and is receiving treatment with GSK. Is currently receiving clinical benefit as determined by the investigator from previous treatment with GSK either as monotherapy or as part of a combination treatment regimen. Is currently participating in a GSK-sponsored study of GSK Patients who are currently participating or planning to participate in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study or who are receiving other investigational agents. Women currently on tamoxifen and raloxefene for prevention are not eligible Currently receiving anti-cancer therapy. Exceptions: Zoledronic acid and denosumab to treat bone metastasis are allowed. Currently participating in any other interventional clinical study Patients currently receiving chemotherapy or radiation therapy. Currently receiving vismodegib, biologics or chemotherapy Currently undergoing treatment with photodynamic therapy, topical chemotherapy agents including imiquimod, fluorouracil, ingenol mebutate (picato) to the selected treatment lesion sites Patients currently entered on Alopexx Oncology Protocol AO- Currently receiving adjuvant trastuzumab (Herceptin) Active malignancy currently undergoing chemo or radiation therapy; hormone therapy is acceptable patient was currently enrolled in Novartis sponsored study, which had met its endpoint and was receiving single agent oral dovitinib or dovitinib and fulvestrant coadministration Patients currently receiving active therapy for other neoplastic disorders PART II: Currently receiving chemotherapy or radiation therapy Patients who are currently receiving active therapy for other neoplastic disorders will not be eligible Patients who are currently receiving lithium chloride (LiCl) Patients who are currently receiving active therapy for other neoplastic disorders will not be eligible Currently receiving other GCTB specific treatment (eg, radiation, chemotherapy, or embolization) Currently receiving (or scheduled to receive) radiation treatment for a cancer listed in the inclusion criteria Patient's household is currently receiving or applying for Supplemental Nutrition Assistance Program (SNAP) benefits (formerly known as food stamps) Patients who are currently receiving physical therapy or practicing yoga for any reason Currently employed in night shift work Currently receiving reflexology or meditative practices Subject must currently be receiving enzalutamide for prostate cancer in a study sponsored by Astellas or Medivation and, based on the investigator's assessment, benefit from continued treatment. Subjects participating in investigator-initiated trials are not eligible. Subject is currently participating in an investigator-initiated interventional trial and receiving enzalutamide. Patients currently receiving anti-convulsants (such as gabapentinoids, e.g. gabapentin (Neurontin) or pregabalin (Lyrica) will be tapered off these medications over days; the study team will provide instructions on how to do this Not currently regularly practicing yoga (defined as at least once a month) Currently receiving home delivered meals from other sources Currently on gabapentin Currently residing in nursing or assisted living facility Currently practicing nurse Subjects currently participating in a RT program Currently between .-. years from the completion of active cancer therapy Patient is currently on antibiotics Currently receiving rehabilitation At the time of recruitment the patient is on active treatment defined as either currently receiving chemotherapy or radiation or less than months post-cancer surgery Currently walking, on average, more than minutes per week Currently receiving anti-convulsants (such as gabapentinoids, e.g. gabapentin [Neurontin] or pregabalin [Lyrica]); all patients on these medications will be weaned off them prior to study initiation Currently receiving other alternative treatment for CDI (e.g. antibiotics other than metronidazole or vancomycin; probiotics; immunoglobulin therapy; fecal transplant) Patients currently using a wearable activity tracker Currently participating in couple/marital therapy Evaluation of Web-based Program: HNSCC patients who are currently undergoing or have recently completed radiation treatment (< years) Currently has breast implant (which limits the performance of many yoga poses) Currently receiving other intravesical chemotherapy. Currently receiving Dilantin (phenytoin) or auranofin or another gold-containing compound Currently receiving immune-modulating therapies Participant is currently receiving treatment with fluvoxamine Participant is currently receiving treatment with immunosuppressants or corticosteroids Participant is currently receiving treatment with nifedipine (Procardia XL) Minocycline trial only: patients who currently have bile duct obstruction or cholelithiasis Currently receiving anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, clonidine, and/or tricyclic drugs (imipramine, clomipramine, or desipramine) Be currently receiving anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and/or tricyclic drugs (imipramine, clomipramine, or desipramine) Currently undergoing treatment for active gynecologic cancer Currently receiving chemotherapy or radiation Subjects may be currently prescribed hormone treatment or Herceptin therapy Patients currently participating in a meditation practice for more than hour per week prior to preoperative visit Patient currently residing in a skilled nursing facility Subjects who will be receiving dasatinib Currently receiving chemotherapy Currently prescribed plavix (clopidogrel) Currently weighs > pounds Currently receiving tamoxifen or raloxifene Currently receiving anticoagulant therapy Currently receiving therapeutic anticoagulant therapy or dual antiplatelet therapy (e.g. aspirin and clopidogrel) Currently on the wait list for a new garden Participants must not be currently receiving or have previously received thiazolidinedione treatment unless sputum atypia or endobronchial dysplasia are documented again after thiazolidinedione treatment and within months of entry PILOTS II and III: Currently receiving radiation therapy or cytotoxic chemotherapy For nicotine replacement therapy (NRT) (patch, gum, lozenge):\r\n* History of severe eczema or any serious skin problem if requested nicotine patch\r\n* History of severe allergic reaction to the nicotine patch or other skin adhesives\r\n* History of heart attack in the last months\r\n* Currently experiencing frequent angina or chest pain related to heart\r\n* Currently experiencing signs and symptoms of peptic ulcer\r\n* Currently receiving medications for rapid or irregular heart beat\r\n* Currently experiencing signs and symptoms of severe, uncontrolled high blood pressure Presence of at least CV risk factor:\r\n* Currently on medication for hypertension, or\r\n* Currently on medication for cholesterol or triglyceride, or\r\n* Currently on medication for diabetes, or\r\n* Currently not physically active (self-reported average < minutes/day), or\r\n* Currently smoking. Currently institutionalized Currently on the wait list for a new garden Currently receiving vismodegib, biologics or chemotherapy Currently undergoing treatment with photodynamic therapy, topical chemotherapy agents including imiquimod, fluorouracil Currently receiving or planning to receive other xerostomia treatment, including drugs, herbs or devices; all other treatments known to affect salivation should be stopped at least days prior to enrollment Currently receiving treatment for any malignancy Not currently undergoing or planning to initiate chemotherapy Subject is currently participating on a separate otoprotection clinical study. Currently receiving immunosuppressive therapy to include chemotherapy, steroids, or methotrexate Subject is currently receiving anticoagulation therapy other than acetylsalicylic acid currently minimally active, Not currently receiving cancer-directed therapy Currently receiving immunotherapy Previously or currently receiving taxane-based chemotherapy Is currently receiving and able to discontinue erlotinib, gefinitib, afatinib, or osimertinib Currently treated for hyperthyroidism Presence of synchronous malignancy for which the patient is currently receiving active treatment Not currently receiving radiation treatment for a cancer listed in the arm-specific inclusion criteria (Arms and ) Currently receiving treatment for a cancer other than those listed in the arm-specific inclusion criteria (exception: the study does not exclude those receiving treatment for non-melanoma skin cancer) (Arms and ) Currently fasts hours or more (on either of two hour diet recalls, conducted during interim ) Patient currently receiving or had prior treatment for the currently diagnosed breast cancer. Are currently receiving other medications or radiation intended for the treatment of their malignancy